全文获取类型
收费全文 | 5403篇 |
免费 | 364篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 150篇 |
妇产科学 | 162篇 |
基础医学 | 592篇 |
口腔科学 | 134篇 |
临床医学 | 370篇 |
内科学 | 1172篇 |
皮肤病学 | 98篇 |
神经病学 | 279篇 |
特种医学 | 108篇 |
外科学 | 970篇 |
综合类 | 248篇 |
一般理论 | 4篇 |
预防医学 | 486篇 |
眼科学 | 158篇 |
药学 | 409篇 |
中国医学 | 32篇 |
肿瘤学 | 331篇 |
出版年
2023年 | 54篇 |
2022年 | 95篇 |
2021年 | 217篇 |
2020年 | 140篇 |
2019年 | 171篇 |
2018年 | 221篇 |
2017年 | 143篇 |
2016年 | 164篇 |
2015年 | 183篇 |
2014年 | 203篇 |
2013年 | 272篇 |
2012年 | 455篇 |
2011年 | 456篇 |
2010年 | 234篇 |
2009年 | 176篇 |
2008年 | 282篇 |
2007年 | 305篇 |
2006年 | 278篇 |
2005年 | 262篇 |
2004年 | 225篇 |
2003年 | 204篇 |
2002年 | 186篇 |
2001年 | 71篇 |
2000年 | 70篇 |
1999年 | 68篇 |
1998年 | 44篇 |
1997年 | 28篇 |
1996年 | 14篇 |
1995年 | 23篇 |
1994年 | 14篇 |
1993年 | 20篇 |
1992年 | 25篇 |
1991年 | 30篇 |
1990年 | 36篇 |
1989年 | 32篇 |
1988年 | 34篇 |
1987年 | 33篇 |
1986年 | 25篇 |
1985年 | 22篇 |
1984年 | 23篇 |
1983年 | 24篇 |
1982年 | 12篇 |
1981年 | 20篇 |
1980年 | 15篇 |
1979年 | 12篇 |
1977年 | 13篇 |
1976年 | 21篇 |
1975年 | 10篇 |
1974年 | 16篇 |
1973年 | 11篇 |
排序方式: 共有5786条查询结果,搜索用时 62 毫秒
51.
Abdel Gawwad E Ahmed MH Kamal MM 《The Journal of the Egyptian Public Health Association》1999,74(1-2):139-173
The purpose of this study is to develop and test the reliability and validity of an Egyptian version of the Children's Health Locus of Control scale. A cross sectional study design was applied using a stratified random sample of 930 students from the final two grades of primary and all grades of the preparatory schools. A further convenience sample of 120 students was selected to examine test-retest reliability of the scale. A preliminary instrument was developed and consisted of 40 statements having one of two response forms; a Yes/No format and a 4-point Likert scale format From data analysis the later format showed higher validity and reliability than the former one. Construct validity of the scale is evidenced by the factor analysis which revealed five factors (Internal, Chance, Powerful Others, Fate and Self blame) consistent with the previous theoretical model of HLC. As indicated by eta coefficient the scale and the subscales showed strong discriminating power between subjects. The known group comparison indicated a good criterion validity of the scale and the subscales. The scale showed a considerable reliability as alpha coefficient was 0.73 with test-retest reliability of 0.65. Comparison of different groups of students indicated that the scale could be used with confidence for all age groups, though it was more reliable for the preparatory phase, for private and governmental schools for males and females and for different social strata. Further testing of the developed scale is indicated among Egyptian children in different cultures. 相似文献
52.
Lydiard RB Perera P Batzar E Clary CM 《Primary care companion to the Journal of clinical psychiatry》1999,1(5):154-162
BACKGROUND: New medications that enter the marketplace have been tested almost exclusively in controlled clinical trials conducted in specialty research settings. There is some concern that these carefully selected patient samples may not provide information generalizable to the "real world" clinical population. The purpose of this investigation was to compare results from a large, open-label study of sertraline in the treatment of major depression in the clinical practice setting with pooled results from 2 multicenter, double-blind, placebo-controlled studies conducted in specialty research settings. METHOD: Clinical practice patients (N = 1482), aged 21 to 65 years, from 228 psychiatric clinical practice sites across the United States participated in the open-label treatment study (Clinical Practice sample). Patients who met DSM-III-R criteria for moderate-to-severe unipolar major depression (i.e., had pretreatment Hamilton Rating Scale for Depression [HAM-D] scores >/= 18) were treated for 8 weeks with sertraline in a flexible dosing fashion (50-200 mg daily). Outcomes on the HAM-D and Clinical Global Impressions-Improvement scale (CGI-I) were compared with the pooled results from 2 previously published placebo-controlled, multicenter treatment studies of sertraline in outpatients with major depression (N = 280). The overall response to sertraline in the Clinical Practice sample was compared with the outcome from the research study patient sample (Clinical Research sample). Additionally, comparison of outcomes of patients with common depressive subtypes (double depression, anxious depression, and melancholic ["endogenous"] depression) were examined. RESULTS: The percentage of sertraline-treated patients rated as responders on the CGI-I was significantly higher in the Clinical Practice sample compared with the Clinical Research sample (87% vs. 73%; p <.001). Sertraline was also much better tolerated in the Clinical Practice sample than in the Clinical Research sample as evidenced by significantly lower overall reports of adverse events (9.4% vs. 13.2%; p <.05) and lower patient dropout rates (17.5% vs. 34.3%; p <.01). Among clinical practice patients, sertraline was found to be equally effective in treating endogenous/melancholic and anxious subtypes and only mildly less effective in achieving a response in patients with double depression (chronic low-grade depression with a superimposed major depression). A regression analysis identified older age and double depression as being predictors of a slower time to response. More than 70% of patients who reported nonresponse to previous treatment with fluoxetine or a tricyclic antidepressant responded to sertraline. CONCLUSION: The effectiveness and tolerability of sertraline treatment was found to be significantly better in the Clinical Practice sample, suggesting that the results from controlled studies in research settings may represent an underestimate of the benefits of a drug. More effectiveness research is needed to confirm and extend these findings. 相似文献
53.
Aruna Perera Keith Hyland Hoa K. Nguyen Robert R. Kane 《Journal of labelled compounds & radiopharmaceuticals》2003,46(5):389-394
Concise methods for the synthesis of 4‐hydroxy‐3‐[2H3]‐methoxyphenylalanine (3‐O‐[2H3]‐methydopa) and 3‐hydroxy‐4‐[2H3]‐methoxyphenylalanine (4‐O‐[2H3]‐methydopa) are described. The 3‐O‐[2H3]‐methydopa is a valuable internal standard for the tandem MS quantification of 3‐O‐methyldopa, a metabolite of value in the diagnosis of aromatic l‐amino acid decarboxylase (AADC) deficiency. Copyright © 2003 John Wiley & Sons, Ltd. 相似文献
54.
Peri-catheter calcification is an unusual and previously unreported complication of central venous (CV) catheterization in
infants. A 1.9 Fr Silastic CV catheter was placed in a term infant for administration of total parenteral nutrition and antibiotics
following intra-abdominal sepsis. The catheter was removed, without complication, at a later date after another septic episode.
Imaging studies performed in the investigation of a possible intra-abdominal abscess revealed a cylindrical density within
a clot in the inferior vena cava (IVC). The density was presumed to be a retained catheter fragment. Further investigation
indicated total occlusion of the IVC. Surgical exploration of the IVC revealed only a calcified thrombus. This case represents
a rare and previously unreported complication of CV catheterization in infants. Diagnosing this condition on radiographic
evidence alone can be difficult. It is hoped that awareness of the potential for this complication will avoid unnecessary
invasive procedures in the future. We also suggest a high level of clinical suspicion and routine Doppler ultrasound investigations
to detect IVC thrombosis when indwelling CV catheters are used in infants.
Accepted: 15 July 1997 相似文献
55.
Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers 总被引:3,自引:4,他引:3
Tang DL; Rundle A; Warburton D; Santella RM; Tsai WY; Chiamprasert S; Hsu YZ; Perera FP 《Carcinogenesis》1998,19(11):1949-1953
This molecular epidemiologic case-control study of lung cancer incorporated
three complementary biomarkers: the glutathione S- transferase M1 (GSTM1)
null genotype, a potential marker of susceptibility, and polycyclic
aromatic hydrocarbon-DNA adducts (PAH- DNA) and sister chromatid exchanges
(SCE), both indicators of environmentally induced genetic damage.
Associations between biomarkers and lung cancer were investigated, as were
possible gene-environment interactions between the GSTM1 null genotype and
tobacco smoke exposure. Subjects included 136 primary non-small cell lung
cancer surgical patients and 115 controls at the Columbia Presbyterian
Medical Center. Questionnaire and Tumor Registry data, pre-treatment blood
samples and biomarker measurements on blood were obtained. Overall, GSTM1
null genotype was significantly associated with lung cancer [odds ratio
(OR) = 2.04, 95% confidence interval (CI) = 1.13-3.68]. ORs for GSTM1 and
lung cancer were significant in females (2.50, 1.09-5.72) and smokers
(2.25, 1.11-4.54) and not significant in males (1.4, 0.58-3.38) and
non-smokers (0.88, 0.18-4.33). However, ORs for males versus females and
smokers versus non-smokers did not differ significantly. The OR for GSTM1
and lung cancer in female smokers was 3.03 (1.09- 8.40), compared with 1.42
(0.53-4.06) in male smokers. In contrast to PAH-DNA adducts in leukocytes,
SCE did not differ between cases and controls. Neither biomarker differed
significantly between the two GSTM1 genotypes. The combined effect of
elevated PAH-DNA adducts and GSTM1 genotype on case-control status (16.19,
1.2-115) appeared multiplicative. Results suggest that the effect of the
GSTM1 null genotype is greatest in female smokers, which is consistent with
other evidence that indicates that women are at higher risk of lung cancer
than males, given equal smoking. Persons with both the GSTM1 deletion and
elevated PAH-DNA adducts may represent a sensitive subpopulation with
respect to carcinogens in tobacco smoke and other environmental media.
相似文献
56.
57.
Kirsti A Bocskay Deliang Tang Manuela A Orjuela Xinhua Liu Dorothy P Warburton Frederica P Perera 《Cancer epidemiology, biomarkers & prevention》2005,14(2):506-511
Molecular and traditional epidemiology studies have indicated a possible relationship between in utero environmental exposures and increased risk for childhood cancers, especially acute leukemias. Chromosomal aberrations have been associated with environmental exposures and cancer risk in adults. In order to more clearly define the association between prenatal exposures to carcinogenic polycyclic aromatic hydrocarbons (PAH) and chromosomal aberrations, chromosomal aberration frequencies were measured in a subset of 60 newborns from the Columbia Center for Children's Environmental Health (CCCEH) Prospective Cohort Study. The subset was composed of African American and Dominican, nonsmoking mother-newborn pairs residing in low-income neighborhoods of New York City, who were exposed to varying levels of airborne PAHs. Prenatal exposure was assessed by questionnaire, personal air monitoring during the third trimester, and PAH-DNA adducts in umbilical cord blood. Chromosomal aberrations were measured in cord blood lymphocytes by fluorescence in situ hybridization. PAH-DNA adducts were not associated with chromosomal aberrations. However, airborne PAHs were significantly associated with stable aberration frequencies in cord blood (P < 0.01). Moreover, stable aberration frequencies were significantly higher among African American newborns compared with Dominican, despite no significant differences in PAH exposure. These results show for the first time an association between prenatal exposure to airborne carcinogenic PAHs and chromosomal aberrations in cord blood, suggesting that such prenatal exposures have the potential to cause cytogenetic damage that has been related to increased cancer risk in other populations. If confirmed, this finding may open new avenues for prevention. 相似文献
58.
Rushika M Perera Yoshitaka Narita Frank B Furnari Hui K Gan Carmel Murone Marika Ahlkvist Rodney B Luwor Antony W Burgess Elisabeth Stockert Achim A Jungbluth Lloyd J Old Webster K Cavenee Andrew M Scott Terrance G Johns 《Clinical cancer research》2005,11(17):6390-6399
Monoclonal antibody (mAb) 806 is a novel epidermal growth factor receptor (EGFR) antibody with significant antitumor activity that recognizes a mutant EGFR commonly expressed in glioma known as delta2-7 EGFR (de2-7 EGFR or EGFRvIII) and a subset of the wild-type (wt) EGFR found in cells that overexpress the receptor. We have used two human xenograft mouse models to examine the efficacy of mAb 806 in combination with mAb 528, a prototypical anti-EGFR antibody with similar specificity to cetuximab. Treatment of nude mice, bearing s.c. or i.c. tumor human xenografts expressing the wt or de2-7 EGFR, with mAbs 806 and 528 in combination resulted in additive and in some cases synergistic, antitumor activity. Interestingly, mAb 528 was also effective against xenografts expressing the ligand independent de2-7 EGFR when used as a single agent, showing that its antitumor activity is not merely mediated through inhibition of ligand binding. When used as single agents, neither mAbs 806 or 528 induced down-regulation of the de2-7 EGFR either in vitro or in vivo. In contrast, the combination of antibodies produced a rapid and dramatic decrease in the total cell surface de2-7 EGFR both in vitro and in xenografts. Consistent with this decrease in total cell surface de2-7 EGFR, we observed up-regulation of the cell cycle inhibitor p27(KIP1) and a decrease in tumor cell proliferation as measured by Ki-67 immunostaining when the antibodies were used in combination in vivo. Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic. 相似文献
59.
60.